fda approval semaglutide mash WEGOVY GETS APPROVAL: The weight-loss drug Wegovy just got to treat a common and serious liver condition known as (Metabolic Dysfunction-Associated Steatohepatitis), adding to a long list of benefits Semaglutide Gets FDA Greenlight for

The starting dose is 2mg administered once weekly by subcutaneous injection

Weight loss typically involves losing both fat and some lean body mass

Additionally, IGF-1 levels, the primary mediator of many GH effects, show dose-dependent increases in response to combined CJC-1295 and Ipamorelin treatment in rodent models

Similarly, if you're pregnant, breastfeeding, or taking insulin, alcohol introduces unacceptable risks to your health and your medication's effectiveness

Dose modeling research suggested that patients might receive even more benefits with little extra risk at a 7.2 mg dose, a concept that was tested in the STEP UP trials (STEP UP Obesity and STEP UP Diabetes)